New drug AMN1126 put through early safety testing
NCT ID NCT06467201
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety and tolerability of a single dose of the experimental drug AMN1126 in 18 healthy postmenopausal women. Participants received one of three different doses (150mg, 300mg, or 600mg) and were monitored for side effects and how the drug moved through their bodies. The study is complete, but it was not designed to treat any disease—only to gather initial safety information.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AMN1126 (KSHN001126)
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY POSTMENOPAUSAL WOMEN are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced Pharma CR
Miami, Florida, 33147, United States
-
Health1 Superspeciality Hospital
Ahmedabad, Gujarat, 380058, India